# Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC

> **NCT00865475** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 38 (actual)

## Conditions studied

- HIV Infection
- HIV Infections

## Interventions

- **DRUG:** AZT+3TC+ABV (Trizivir)
- **DRUG:** Switching to LPV/r monotherapy (Kaletra)

## Key facts

- **NCT ID:** NCT00865475
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2013-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00865475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00865475, "Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00865475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*